News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,288 Results
Type
Article (862)
Company Profile (2)
Press Release (2424)
Multimedia
Podcasts (17)
Webinars (1)
Section
Business (1426)
Career Advice (20)
Deals (183)
Drug Delivery (10)
Drug Development (613)
Employer Resources (10)
FDA (99)
Job Trends (177)
News (2016)
Policy (148)
Tag
Academia (11)
Accelerated approval (3)
ADA (1)
Alliances (185)
ALS (2)
Alzheimer's disease (8)
Antibody-drug conjugate (ADC) (1)
Approvals (93)
Artificial intelligence (3)
Autoimmune disease (8)
Bankruptcy (2)
Best Places to Work (111)
BIOSECURE Act (2)
Biosimilars (1)
Biotechnology (1)
Breast cancer (1)
Cancer (15)
Cardiovascular disease (7)
Career advice (16)
CAR-T (7)
Cell therapy (25)
Clinical research (426)
Collaboration (12)
Compensation (4)
Complete response letters (2)
COVID-19 (13)
CRISPR (32)
C-suite (30)
Cystic fibrosis (41)
Data (28)
Diabetes (9)
Diagnostics (5)
Diversity, equity & inclusion (2)
Drug discovery (5)
Drug pricing (10)
Duchenne muscular dystrophy (6)
Earnings (388)
Editorial (3)
Employer branding (6)
Employer resources (8)
Events (471)
Executive appointments (19)
FDA (119)
Funding (24)
Gene editing (50)
Gene therapy (52)
GLP-1 (20)
Government (39)
Guidances (4)
Healthcare (45)
Hematology (1)
Huntington's disease (2)
IgA nephropathy (20)
Immunology and inflammation (9)
Immuno-oncology (2)
Indications (1)
Infectious disease (13)
Intellectual property (1)
Interviews (3)
IPO (56)
Job creations (68)
Job search strategy (13)
JPM (2)
Labor market (3)
Layoffs (6)
Leadership (2)
Legal (18)
Lung cancer (4)
Lymphoma (1)
Manufacturing (8)
Medical device (15)
Medtech (15)
Mergers & acquisitions (129)
Metabolic disorders (20)
mRNA (8)
Multiple sclerosis (2)
Neurodegenerative disease (6)
Neuropsychiatric disorders (1)
Neuroscience (22)
NextGen: Class of 2026 (51)
Non-profit (14)
Now hiring (4)
Obesity (10)
Opinion (14)
Pain (31)
Parkinson's disease (1)
Partnered (1)
Patents (1)
Patient recruitment (2)
People (648)
Pharmaceutical (1)
Phase 1 (153)
Phase 2 (233)
Phase 3 (160)
Pipeline (59)
Policy (14)
Postmarket research (18)
Preclinical (36)
Radiopharmaceuticals (2)
Rare diseases (94)
Real estate (57)
Recruiting (4)
Regulatory (159)
Research institute (5)
Resumes & cover letters (5)
RSV (1)
Schizophrenia (2)
Series A (6)
Series B (4)
Sickle cell disease (38)
Special edition (3)
Spinal muscular atrophy (1)
Startups (35)
Supply chain (1)
Tariffs (6)
The Weekly (17)
Vaccines (9)
Venture capital (4)
Weight loss (5)
Date
Last 7 days (6)
Last 30 days (21)
Last 365 days (201)
2026 (110)
2025 (218)
2024 (270)
2023 (222)
2022 (231)
2021 (254)
2020 (260)
2019 (197)
2018 (183)
2017 (221)
2016 (137)
2015 (210)
2014 (79)
2013 (67)
2012 (88)
2011 (122)
2010 (67)
Location
Africa (13)
Alabama (1)
Asia (96)
Australia (19)
California (42)
Canada (15)
China (15)
Colorado (1)
Europe (518)
Illinois (4)
Japan (2)
Maryland (7)
Massachusetts (203)
Minnesota (1)
Montana (1)
New Hampshire (5)
New Jersey (5)
New York (11)
North Carolina (9)
Northern California (17)
Ohio (2)
Pennsylvania (5)
South America (13)
Southern California (19)
Tennessee (1)
Texas (2)
United States (291)
Utah (1)
Washington State (4)
3,288 Results for "vertex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for their recently approved IgAN therapies Fabhalta and Trutakna.
July 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Vertex inks $10B Crinetics buy, entering ‘white space blockbuster opportunity’
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets.
July 7, 2026
·
2 min read
·
Tristan Manalac
Earnings
Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.
May 5, 2026
·
2 min read
·
Tristan Manalac
Podcast
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.
July 8, 2026
·
1 min read
·
Jef Akst
Earnings
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.
February 13, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.
March 10, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Acquire Crinetics Pharmaceuticals
July 7, 2026
·
19 min read
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program.
July 2, 2026
·
2 min read
·
Tristan Manalac
Earnings
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.
November 4, 2025
·
5 min read
·
Tristan Manalac
Press Releases
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
July 7, 2026
·
1 min read
1 of 329
Next
